Media Home
UN Web TV
UN Audiovisual Library
UN PhotoEBOLA / VACCINES
Download
There is no media available to download.
Share
STORY: EBOLA / VACCINES
TRT: 1.46
SOURCE: WHO
RESTRICTIONS: NONE
LANGUAGE: ENGLISH /NATS
DATELINE: 9 JANUARY 2015, GENEVA, SWITZERLAND
1. Wide shot, press room
2. Close up, journalist
3. SOUNDBITE (English) Dr Marie-Paule Kieny, Assistant Director-General, WHO:
“We know now that so far, the two vaccines that have already undergone the first phase of testing which looks at safety and immunogenicity, so does it induce an immune response, have an acceptable safety profile. So that is really a good news it means that these two vaccines which are the most advanced are continuing their journey towards evaluation.”
4. Cutaway, cameras
5. SOUNDBITE (English) Dr Marie-Paule Kieny, Assistant Director-General, WHO:
“These trials are about to being for the two lead vaccines, again...the chimp adenovirus developed by GSK, the VSK developed by Merck, and we have already been informed of plans of a third manufacturer, Johnson and Johnson to also engage into efficacy testing. “
6. Cutaway, journalists
7. SOUNDBITE (English) Dr Marie-Paule Kieny, Assistant Director-General, WHO:
“The Liberia trial is meaning to test the two vaccines, so they would be able to start by the end of the month when the vaccine manufacturers, the first vaccine manufacturer has made a final decision on which dose level they would start. So they would be able to start in end of January, potentially, the Sierra Leone trial is now announced to start in February, and the Guinea trial is also meant to start in February.”
8. Cutaway, press room
World Health Organization (WHO) said today two most promising Ebola vaccines have “an acceptable safety profile” and are soon to be tested in affected areas in West Africa.
Following a two-day high-level meeting in Geneva, the WHO assistant director-general Marie-Paule Kieny announced at the press conference today that “the two vaccines that have already undergone the first phase of testing which looks at safety and immunogenicity, so does it induce an immune response, have an acceptable safety profile.”
Two vaccines are the chimp adenovirus developed by GlaxoSmithKline, the VSK developed by Merck. Kieny also said that “Johnson and Johnson is to also engage into efficacy testing.”
The next phase of testing is to take place on healthy people in West Africa.
Keiny said to trials in Liberia are to “start in end of January, potentially, the Sierra Leone trial is now announced to start in February, and the Guinea trial is also meant to start in February.”
According to WHO statistics, there have been in excess of 20 000 confirmed, probable, and suspected cases of Ebola Virus as of 7 January, with more than 8000 deaths.
